RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC
  3. Raw

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$109.6B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2010		Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Product revenues, net--------3,0484,1636,2067,5748,9319,86911,020
Cost of sales--------4105487369041,0801,2621,531
Research and development expenses------------2,5403,1633,630
Acquired in-process research and development expenses-------------5274,600
Selling, General and Administrative Expense1884014373623053774334965586587708409451,1371,464
Change in fair value of contingent consideration---------413-3-57-52-0
Total costs and expenses8391,2971,5252,1151,2731,4991,6922,3652,4122,9653,3494,7924,6236,03711,253
(Loss) income from operations-6961142-903-692-467101236351,1982,8562,7824,3073,832-233
Interest income---------64225145615598
Interest expense--------------31
Other income (expense), net----5030-74-81-11922965-165-23-86
Income before provision for income taxes-----------2,7304,2324,380249
Provision for income taxes-1939-28973017-107-1,487218405388910760784
Net (loss) income-75541-51-445-739-556-842632,0971,1772,7122,3423,3223,620-536
Earnings Per Share, Basic-3.770.14-0.5-1.98-3.14-2.31-0.461.068.244.5810.449.0912.9714.05-2.08
Earnings Per Share, Diluted-3.770.14-0.5-1.98-3.14-2.31-0.461.048.094.5110.299.0112.8213.89-2.08